SEC Comment Letter for Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Mar 25, 2010

Aptose Biosciences Inc. (CIK 0000882361)
Date: March 25, 2010 · CIK: 0000882361 · Accession: 0000000000-10-016487

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-32001

Date

March 22, 2010

Author

Not clearly detected

Form

UPLOAD

Company

Aptose Biosciences Inc. (CIK 0000882361)

Letter

Via Facsimile and U.S. Mail Mail Stop 4720 March 22, 2010 Elizabeth Williams Director of Finance and Ac ting Chief Financial Officer Lorus Therapeutics Inc. 2 Meridian Road Toronto, Ontario, Canada M9W 4Z7

Re: Lorus Therapeutics Inc. Form 20-F for the Fiscal Year Ended May 31, 2009 Filed November 30, 2009 File Number: 001-32001

Dear Ms. Williams:

We have completed our review of your Form 20-F and have no further comments at this time. S i n c e r e l y , Joel Parker A c c o u n t i n g B r a n c h C h i e f

Show Raw Text

Via Facsimile and U.S. Mail
Mail Stop 4720

         March 22, 2010

Elizabeth Williams
Director of Finance and Ac ting Chief Financial Officer
Lorus Therapeutics Inc. 2 Meridian Road
Toronto, Ontario, Canada
M9W 4Z7

Re: Lorus Therapeutics Inc.
Form 20-F for the Fiscal Year Ended May 31, 2009
Filed November 30, 2009
 File Number:  001-32001

Dear Ms. Williams:

  We have completed our review of your Form 20-F and have no further comments
at this time.            S i n c e r e l y ,
Joel Parker
        A c c o u n t i n g  B r a n c h  C h i e f

SecProbe.io